Novartis’s Kymriah becomes first gene therapy to get FDA approval – The Cancer Letter Publications
|
Novartis's Kymriah becomes first gene therapy to get FDA approval
The Cancer Letter Publications The agent, sponsored by Novartis Pharmaceuticals Corp., was approved for pediatric and young adult patients with a form of acute lymphoblastic leukemia. On July 12, the FDA Oncologic Drugs Advisory Committee unanimously recommended that the agent … |
